Serina Therapeutics, Inc. (SER)
NYSEAMERICAN: SER · Real-Time Price · USD
1.817
-0.003 (-0.16%)
May 1, 2026, 4:00 PM EDT - Market closed
Serina Therapeutics Employees
As of December 31, 2024, Serina Therapeutics had 13 total employees, including 12 full-time and 1 part-time employees. The number of employees increased by 2 or 18.18% compared to the previous year.
Employees
13
Change (1Y)
2
Growth (1Y)
18.18%
Revenue / Employee
$10,000
Profits / Employee
-$1,495,077
Market Cap
22.37M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 13 | 2 | 18.18% | 12 | 1 |
| Dec 31, 2023 | 11 | - | - | 9 | 2 |
| Sep 30, 2023 | 9 | - | - | 5 | 4 |
| Jun 30, 2023 | 9 | - | - | 5 | 4 |
Related Stocks
| Company Name | Employees |
|---|---|
| Vistagen Therapeutics | 59 |
| Quince Therapeutics | 38 |
| Curis | 24 |
| OSR Holdings | 22 |
| Lantern Pharma | 16 |
| VYNE Therapeutics | 10 |
| AEON Biopharma | 8 |
| Exicure | 8 |
SER News
- 26 days ago - Serina Therapeutics to Present at the 5th LNP Formulation & Process Development Summit - GlobeNewsWire
- 4 weeks ago - Serina Therapeutics Announces NYSE American Acceptance of Continued Listing Compliance Plan - GlobeNewsWire
- 5 weeks ago - Serina Therapeutics to Present at the 38th Annual Roth Conference - GlobeNewsWire
- 6 weeks ago - Serina Therapeutics Secures up to $30 Million in Private Placement to Advance Registrational Trial of SER-252 for Advanced Parkinson's Disease - GlobeNewsWire
- 2 months ago - Serina Therapeutics Announces Dosing of First Patient in Phase 1b Registrational Trial of SER-252 for Advanced Parkinson's Disease - GlobeNewsWire
- 2 months ago - Serina Therapeutics Announces First Patient Enrolled in Phase 1b Registrational Trial of SER-252 for Advanced Parkinson's Disease - GlobeNewsWire
- 3 months ago - Registration Is Now Open For Tribe Public's CEO Presentation and Q&A Webinar Event - GlobeNewsWire
- 3 months ago - Serina Therapeutics Announces FDA Clearance of IND Application for SER-252 for the Treatment of Advanced Parkinson's disease - GlobeNewsWire